Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Olstein Capital Management L.P.

Olstein Capital Management L.P. reduced its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 133,000 shares of the life sciences company’s stock after selling 22,000 shares during the quarter. Olstein Capital Management L.P.’s holdings in Integra LifeSciences were worth $3,016,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Sachem Head Capital Management LP purchased a new position in shares of Integra LifeSciences in the 3rd quarter valued at approximately $44,153,000. Dimensional Fund Advisors LP increased its stake in Integra LifeSciences by 0.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after purchasing an additional 12,766 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Integra LifeSciences by 15.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after buying an additional 125,620 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in shares of Integra LifeSciences by 64.6% during the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after buying an additional 335,557 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its position in shares of Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after acquiring an additional 405,624 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on IART shares. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research report on Tuesday, November 5th. Bank of America dropped their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research report on Monday, October 7th. BTIG Research raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Finally, Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $23.00.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $26.05 on Friday. The company has a market capitalization of $2.01 billion, a PE ratio of -289.41, a price-to-earnings-growth ratio of 0.83 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company’s fifty day moving average price is $23.32 and its 200 day moving average price is $22.33. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. During the same period in the prior year, the company posted $0.76 EPS. The company’s revenue for the quarter was down .4% on a year-over-year basis. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.